ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

More Bad News for AVEO As Tivozanib Partner Bids Adieu

May 31, 2013

Cooperative Group Leadership Changes: Decosse Heads CCIRC, Hoogstraten Chairmen’s Committee

July 8, 1977

White House Okays Committee ‘Kill’ Lists; Workshops To Plan Projects In Carcinogenesis

July 22, 1977

Gallo Actively Searching For New Position

July 1, 1994

NCI Adds New Wrinkle To Drug Distribution Plan – Individual Investigators To Work Through Centers

March 25, 1977

Interview: Von Eschenbach Says His Goal Is to Speed Development of Interventions

March 29, 2002